Keyphrases
Dialysis
100%
Clopidogrel
100%
P2Y12 Inhibitors
100%
Bleeding Risk
100%
Gastrointestinal Bleeding
100%
Intracranial Bleeding
100%
End-stage Kidney Disease
83%
Prasugrel
66%
Ticagrelor
66%
Intracranial Bleed
66%
Bleeding
33%
P2Y12
33%
High Risk
16%
Coronary Artery Disease
16%
Clinical Trials
16%
Retrospective Cohort Study
16%
Gastrointestinal
16%
Aging Effect
16%
Annual Incidence
16%
Incidence Rate
16%
Increasing Age
16%
Fast-growing
16%
United States Renal Data System (USRDS)
16%
Inhibitor Therapy
16%
Bleeding Events
16%
Age-specific Incidence
16%
Bleeding Complications
16%
Cardiovascular Therapy
16%
Growing Population
16%
Antiplatelet Drugs
16%
Dialysis Patients
16%
Maintenance Hemodialysis
16%
Age Cutoff
16%
Thromboembolism Prevention
16%
Maintenance Peritoneal Dialysis
16%
Nursing and Health Professions
Gastrointestinal Hemorrhage
100%
Ciclonicate
100%
Brain Hemorrhage
100%
Clopidogrel
60%
End Stage Renal Disease
50%
Prasugrel
40%
Ticagrelor
40%
Drug Therapy
10%
Hemodialysis
10%
Cohort Analysis
10%
Bleeding
10%
Coronary Artery Disease
10%
Thrombosis Prevention
10%
Peritoneal Dialysis
10%
Pharmacology, Toxicology and Pharmaceutical Science
Brain Hemorrhage
100%
Gastrointestinal Hemorrhage
100%
Ciclonicate
100%
Clopidogrel
60%
End Stage Renal Disease
50%
Ticagrelor
40%
Prasugrel
40%
Bleeding
10%
Clinical Trial
10%
Coronary Artery Disease
10%
Cohort Study
10%
Thrombosis
10%
Antiplatelet
10%
Neuroscience
Clopidogrel
100%
Ticagrelor
66%
Prasugrel
66%
P2Y12
33%
Cerebral Hemorrhage
16%